Ankeet S. Bhatt, MD, MBA
@ankeetbhatt
Crit. Care Cardiologist @kpdor|Adjunct Prof. @StanfordMed|Prior @MassGenBrigham @IMresidencyDuke| Interests =Trials + ImpSci | AE @JCardFail | Tweet≠endorse
Looking forward to a new position as Director of Interventional Cardiology at Mass General Brigham. With incredible colleagues throughout the system, we will build the most comprehensive IC program internationally.
Thank you to all IAF participants who came together today to share insights, spark ideas, and drive progress in advancing heart health. Your voices and vision are shaping the future of cardiovascular care.🎆 bit.ly/3oGbHeU #TransformCVCare
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial Tirzepatide consistently reduced the risk of HF or cardiovascular death regardless of baseline BMI, but there was evidence suggesting greater improvement in…
Today, we take the next step in Verve’s journey: the acquisition by @EliLillyandCo is now complete. From the founding of Verve in 2018 to this milestone in 2025, we have worked with urgency and conviction to advance a bold idea — that a single-course gene editing medicine could…
Example of AI breaking artificial siloes of medical expertise. @morgancheatham made this point eloquently in his recent @NEJM AI Grand Rounds podcast.
Congrats @David_Ouyang on what will be transformational work at the intersection of CKM health, evaluating #opportunistic screening & #ImplementationScience to improve population health!! @American_Heart @HeartDocSadiya @KPDOR newsroom.heart.org/news/researche…
Congrats @David_Ouyang on what will be transformational work at the intersection of CKM health, evaluating #opportunistic screening & #ImplementationScience to improve population health!! @American_Heart @HeartDocSadiya @KPDOR newsroom.heart.org/news/researche…
We are excited to work with @StanfordDeptMed, @SmidtHeart, @mghliver, and @KPDOR with the support of @American_Heart to refine and prospectively evaluate AI opportunistic screening approaches for Cardiovascular-Kidney-Metabolic Health! Chronic Liver and Kidney Disease is common…
We are excited to work with @StanfordDeptMed, @SmidtHeart, @mghliver, and @KPDOR with the support of @American_Heart to refine and prospectively evaluate AI opportunistic screening approaches for Cardiovascular-Kidney-Metabolic Health! Chronic Liver and Kidney Disease is common…
Huge congrats to @thomasjwang1, incoming Dean of @UMichMedSchool!! Both current (M. Runge) & incoming Deans are translational cardiovascular physician-scientists & graduates of @MGHCVFellows michiganmedicine.org/news-release/t… @UMich
Outstanding training. Unmatched mentorship. Committed to training the next generation of CV leaders! 🫀 #ACCFIT #AHAFIT @ISHVnews @InovaCVfellows vimeo.com/1096404491
Cardiovascular Disease Fellowship Program @ISHVnews Honored to train the next leaders in the field · World Class Faculty · Dedicated Mentoring · Complex Patient Care · Outstanding Research Opportunities · Commitment to Innovation and Excellence vimeo.com/1098619654
We congratulate @thomasjwang1 on becoming the new Dean of @UMich Medical School and we thank him for his significant contributions to our Department! @UTSWMedCenter utsouthwestern.edu/departments/in…
We are hiring at @CTCPR_ 👇 Come join the most innovative and creative team, and help us in redefining how we should conduct randomized controlled trials in a more efficient and inclusive way. Se dette job hos Herlev og Gentofte Hospital: linkedin.com/jobs/view/4269…
AstraZeneca announces $50 billion U.S. investment in Manufacturing in Boston The facility, which will produce drugs for weight management, including #GLP-1s, will be the “cornerstone” of the new investments in the U.S. statnews.com/2025/07/21/ast… via @statnews
Sodium-Glucose Cotransporter 2 Inhibitors and Atherosclerosis The atheroprotective advantages of SGLT2i are attributed to multiple mechanisms, including modulation of inflammatory pathways, improvements in vascular function, and reductions in oxidative stress, in addition to…
Honored to have been featured in the @GMedPhysicians Evidence in Action series, presentin a clinical case based on the latest research in heart failure. A great opportunity to support peer-to-peer learning and global clinical dialogue. #ClinicalCase #HeartFailure
ESC Congress 2025 29 August-1 September 2025 Clinical trials are expected to provide critical data to support further development Coronary Artery Disease and Interventions MACROS-2: RCT of ESC 0/1 versus 0/3 hour ADP for suspected ACS Complete revascularisation versus usual…
A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial In this nationwide pragmatic, 2x2 factorial implementation trial, electronic…
▶️ We will be formally presenting our publication of the @LancetRH_Europe Series on Cardiovascular Disease Inequalities & Disparities at the @escardio ESC Congress in Madrid Location on Friday, August 29, 13:45 – 15:00. Do join us!
🚨 Live from DC: The #ACC Industry Advisory Forum kicks off with a full day focused on Implementation Science — the critical bridge between discovery and delivery in cardiovascular care. Here’s what you need to know. 🧵@ACCinTouch #transformcvcare
Proud of our #HFC members’ outstanding work! Bravo Dr. @ankeetbhatt 👏🏼👏🏼👏🏼
Dr. @ankeetbhatt offers perspective on implementation science, “the scientific study of methods and strategies that facilitate the uptake of evidence-based practice and research into regular use by practitioners and policymakers." bit.ly/3oGbHeU #TransformCVCare